Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03938337 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03938337: Clinical Trial Phase 2 study, sponsored by University of Alabama at Birmingham.
NCT03938337 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03938337, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
To assess the objective response rate of tumor lesions to abemaciclib in combination with pembrolizumab in patients with metastatic or recurrent squamous cell carcinoma of head and neck.
Primary Outcome
Patients will be evaluated for their tumor response to treatment using RECIST criteria on their scans
Interventions
- DRUG Cohort 1 Not Previously Treated
- DRUG Cohort 2 Treated Previously
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-10-08 |
| Est. Completion | 2020-04-03 |
| Phase | Phase 2 |
Why NCT03938337 stopped before completion
NCT03938337 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Cohort 1 Not Previously Treated is the first listed.
NCT03938337 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03938337 about?
NCT03938337 is a clinical study titled "Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer". To assess the objective response rate of tumor lesions to abemaciclib in combination with pembrolizumab in patients with metastatic or recurrent squamous cell carcinoma of head and neck.
What is the current status of trial NCT03938337?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-10-08. Estimated completion is 2020-04-03.
What interventions are being tested in trial NCT03938337?
The interventions under investigation include: Cohort 1 Not Previously Treated (DRUG), Cohort 2 Treated Previously (DRUG).
Who is sponsoring clinical trial NCT03938337?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03938337's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI